期刊
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
卷 14, 期 2, 页码 187-196出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2007.10.006
关键词
t(8;21); AML; hematopoietic stem cell transplantation; chemotherapy
资金
- NCI NIH HHS [U24 CA076518-09, U24 CA076518, U24 CA076518-08, U24-CA76518, U24 CA076518-10] Funding Source: Medline
We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission. Outcomes of 118 patients receiving HCT and reported to the Center for International Blood and Marrow Transplant Research were compared with 132 similar patients receiving chemotherapy selected from 8 German AML Intergroup multicenter trials. Characteristics of the cohorts were similar except that chemotherapy recipients were significantly older. To adjust for time to treatment bias, outcomes were compared using left-truncated Cox regression models. Transplants were associated with higher treatment-related mortality (TRM; relative risk [RR] 6.76, 95% confidence interval [CI] 2.95-15.45, P < .001), lower relapse (RR0.47,95% CI0.25-0.85,P = .01), and similar relapse-free survival (P =.2). Loss of sexchromosomes (LOS) in addition to t(8;2 1) had a negative impact on overall survival (OS) in patients receiving chemotherapy. Patients without LOS experienced shorter survival after HCT comparing to chemotherapy (RR 3.05, P = .02), whereas patients with LOS had similar survival regardless of postremission therapy. In both cohorts, white blood cell count (WBC) at diagnosis > 25 x 10(9)/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P =.008), and OS (RR = 1.91, P = .01). In this cohort of patients with t(8;21) AML, HCT did not improve OS, because reduction of relapse was offset by high TRM. In the group without LOS, survival after chemotherapy was far superior to HCT. These results suggest that patients with t(8;2 1) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据